- Brentuximab vedotin treatment in clinical practice2018 | Third Faculty of Medicine
- Brentuximab vedotin in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma patients2013 | Faculty of Medicine in Hradec Králové
- Current treatment approaches in patients with newly diagnosed peripheral T-cell lymphoma and novel therapies-focusing on brentuximab vedotin2020 | Faculty of Medicine in Hradec Králové
- Brentuximab vedotin consolidation therapy after autologous stem cell transplantation in relapsed/refractory classic Hodgkin lymphoma patients in the Czech Republic2023 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- Brentuximab vedotin in the treatment of lymphomas - practical experience2015 | Third Faculty of Medicine
- Brentuximab vedotin in the treatment of relapsed CD30 positive cutaneous lymphoma - results of an international, open label, randomised, phase 3, multicentre trial - ALCANZA2018 | Faculty of Medicine in Hradec Králové
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. SGN35-010Publication without faculty affiliation
- Pembrolizumab plus enfortumab vedotin in urothelial cancer2024 | Faculty of Medicine in Pilsen
- Report of University Hospital Hradec Králové to the clinical trial protocol No: SGN35-014Publication without faculty affiliation
- Research Report University Hospital for clinical assessment SGN35-014Publication without faculty affiliation
- Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group2016 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Treatment of Refractory Systemic Hodgkin Lymphoma and Secondary CNS Involvement with Brentuximab Vedoti2021 | Third Faculty of Medicine
- Treatment and Prognosis of Relapsed or Refractory Hodgkin Lymphoma Patients Ineligible for Stem Cell Transplantation2014 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world2022 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Komentář ke studii: Brentuximab vedotin v léčbě relabujícího/refrakterního Hodgkinova lymfomu - metaanalýza2015 | Third Faculty of Medicine
- Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study2023 | First Faculty of Medicine
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial2019 | Faculty of Medicine in Hradec Králové
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma2022 | Faculty of Medicine in Hradec Králové
- Polatuzumab vedotin v léčbě agresivních lymfomů2023 | First Faculty of Medicine
- Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy2018 | First Faculty of Medicine
- Léčba relapsu Hodgkinova lymfomu po autologní transplantaci monoterapií brentuximab vedotinem2017 | Third Faculty of Medicine
- Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma2022 | First Faculty of Medicine
- Advanced stages of classical Hodgkin lymphoma - first-line treatment options2021 | Third Faculty of Medicine
- Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement2020 | Third Faculty of Medicine, Second Faculty of Medicine
- Current treatment approaches in patients with advanced-stage Hodgkin lymphoma2014 | Third Faculty of Medicine
- Hodgkin's Lymhoma - the Treatment Aproaches Development and Current Trends2015 | First Faculty of Medicine
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study2021 | First Faculty of Medicine
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial2016 | First Faculty of Medicine
- Hodgkin lymphoma - hendless story Hodgkin lymphoma - endless story2019 | Third Faculty of Medicine